mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Authors:
- Andreas OuranidisAOAndreas Ouranidis
- Theofanis VavilisTVTheofanis Vavilis
- Evdokia MandalaEMEvdokia Mandala
- Christina DavidopoulouCDChristina Davidopoulou
- Eleni StamoulaESEleni Stamoula
- Catherine K. MarkopoulouCMCatherine K. Markopoulou
- Anna KaragianniAnna Karagianni
- Kyriakos KachrimanisKyriakos Kachrimanis
Open Access
- 27 December 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (1) , 50
Abstract
In the quest for a formidable weapon against the SARS-CoV-2 pandemic, mRNA therapeutics have stolen the spotlight. mRNA vaccines are a prime example of the benefits of mRNA approaches towards a broad array of clinical entities and druggable targets. Amongst these benefits is the rapid cycle “from design to production” of an mRNA product compared to their peptide counterparts, the mutability of the production line should another target be chosen, the side-stepping of safety issues posed by DNA therapeutics being permanently integrated into the transfected cell’s genome and the controlled precision over the translated peptides. Furthermore, mRNA applications are versatile: apart from vaccines it can be used as a replacement therapy, even to create chimeric antigen receptor T-cells or reprogram somatic cells. Still, the sudden global demand for mRNA has highlighted the shortcomings in its industrial production as well as its formulation, efficacy and applicability. Continuous, smart mRNA manufacturing 4.0 technologies have been recently proposed to address such challenges. In this work, we examine the lab and upscaled production of mRNA therapeutics, the mRNA modifications proposed that increase its efficacy and lower its immunogenicity, the vectors available for delivery and the stability considerations concerning long-term storage.Keywords
Funding Information
- EYDE-ETAK (Τ2ΕΔΚ—04337)
This publication has 238 references indexed in Scilit:
- Liposome: classification, preparation, and applicationsDiscover Nano, 2013
- Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding ErythropoietinMolecular Therapy, 2012
- A system for the continuous directed evolution of biomoleculesNature, 2011
- pH-Responsive Nanoparticles for Drug DeliveryMolecular Pharmaceutics, 2010
- Human mitochondrial mRNAs—like members of all families, similar but differentBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2010
- RNA Isolation from Mammalian Cells Using Porous Polymer Monoliths: An Approach for High-Throughput AutomationAnalytical Chemistry, 2010
- The Many Pathways of RNA DegradationCell, 2009
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- Development of Stable Influenza Vaccine Powder Formulations: Challenges and PossibilitiesPharmaceutical Research, 2008
- Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cellsRNA, 2007